Is Summit Therapeutics Stock a Good Investment?
Summit Therapeutics Investment Advice | SMMT |
- Examine Summit Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Summit Therapeutics' leadership team and their track record. Good management can help Summit Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Summit Therapeutics' business and its evolving consumer preferences.
- Compare Summit Therapeutics' performance and market position to its competitors. Analyze how Summit Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Summit Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Summit Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Summit Therapeutics PLC stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Summit Therapeutics PLC is a good investment.
Sell | Buy |
Hold
Market Performance | OK | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Summit Therapeutics Stock
Researching Summit Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 84.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.23. Summit Therapeutics PLC had not issued any dividends in recent years. The entity had 1:1 split on the 21st of September 2020.
To determine if Summit Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Summit Therapeutics' research are outlined below:
| Summit Therapeutics is way too risky over 90 days horizon | |
| Summit Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (614.93 M) with profit before overhead, payroll, taxes, and interest of 705 K. | |
| Summit Therapeutics PLC currently holds about 121.97 M in cash with (76.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61. | |
| Summit Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 84.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from businesswire.com: Summit Therapeutics to Present at Upcoming Investor Conferences |
Summit Therapeutics Quarterly Accounts Payable |
|
Summit Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Summit Therapeutics PLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Summit Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Summit Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Summit Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-10-30 | 2024-09-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2024-08-06 | 2024-06-30 | -0.06 | -0.09 | -0.03 | 50 | ||
2019-06-26 | 2019-03-31 | -0.16 | -0.2 | -0.04 | 25 | ||
2017-06-14 | 2017-03-31 | -0.17 | -0.096 | 0.074 | 43 | ||
2019-03-27 | 2018-12-31 | -0.24 | -0.35 | -0.11 | 45 | ||
2019-12-17 | 2019-09-30 | -0.4 | -0.22 | 0.18 | 45 | ||
2018-06-05 | 2018-03-31 | -0.75 | -0.52 | 0.23 | 30 | ||
2016-05-10 | 2016-03-31 | -0.86 | -0.55 | 0.31 | 36 |
Know Summit Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Summit Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Summit Therapeutics PLC backward and forwards among themselves. Summit Therapeutics' institutional investor refers to the entity that pools money to purchase Summit Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | First Trust Advisors L.p. | 2024-06-30 | 788.1 K | Pictet Asset Manangement Sa | 2024-06-30 | 708.6 K | Td Asset Management Inc | 2024-09-30 | 694.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 674.2 K | Citadel Advisors Llc | 2024-09-30 | 650.8 K | Goldman Sachs Group Inc | 2024-06-30 | 453.9 K | Balyasny Asset Management Llc | 2024-09-30 | 431.2 K | D. E. Shaw & Co Lp | 2024-09-30 | 402.2 K | Barclays Plc | 2024-06-30 | 387.3 K | Baker Bros Advisors Lp | 2024-09-30 | 24.4 M | Vanguard Group Inc | 2024-09-30 | 10.9 M |
Summit Therapeutics' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 14.16 B.Market Cap |
|
Summit Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.06) | (2.91) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (3.03) | (2.88) | |
| Return On Equity | (7.91) | (7.52) |
Determining Summit Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Summit Therapeutics is a good buy. For example, gross profit margin measures Summit Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Summit Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Summit Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Summit Therapeutics PLC. Check Summit Therapeutics' Beneish M Score to see the likelihood of Summit Therapeutics' management manipulating its earnings.
Evaluate Summit Therapeutics' management efficiency
Summit Therapeutics PLC has return on total asset (ROA) of (0.3147) % which means that it has lost $0.3147 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7321) %, meaning that it created substantial loss on money invested by shareholders. Summit Therapeutics' management efficiency ratios could be used to measure how well Summit Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -2.91 in 2024. Return On Capital Employed is likely to drop to -0.52 in 2024. At this time, Summit Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 110.1 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 11 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.13 | 0.12 | |
| Net Current Asset Value | 128.1 K | 113.8 K | |
| Tangible Asset Value | 128.1 K | 113.8 K | |
| Tangible Book Value Per Share | 0.12 | 0.12 | |
| Enterprise Value Over EBITDA | 1.7 K | 1.7 K | |
| Price Book Value Ratio | 20.82 | 19.78 | |
| Enterprise Value Multiple | 1.7 K | 1.7 K | |
| Price Fair Value | 20.82 | 19.78 | |
| Enterprise Value | 1.7 B | 1.7 B |
Summit Therapeutics PLC has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta (0.92) |
Basic technical analysis of Summit Stock
As of the 28th of November, Summit Therapeutics has the Coefficient Of Variation of 1008.35, risk adjusted performance of 0.085, and Semi Deviation of 5.31. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Summit Therapeutics PLC, as well as the relationship between them.Summit Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Summit Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Summit Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Summit Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Summit Therapeutics' Outstanding Corporate Bonds
Summit Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Summit Therapeutics PLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Summit bonds can be classified according to their maturity, which is the date when Summit Therapeutics PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Summit Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Summit Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.085 | |||
| Market Risk Adjusted Performance | 0.3294 | |||
| Mean Deviation | 5.64 | |||
| Semi Deviation | 5.31 | |||
| Downside Deviation | 5.8 | |||
| Coefficient Of Variation | 1008.35 | |||
| Standard Deviation | 9.46 | |||
| Variance | 89.58 | |||
| Information Ratio | 0.0854 | |||
| Jensen Alpha | 0.5786 | |||
| Total Risk Alpha | (0.56) | |||
| Sortino Ratio | 0.1393 | |||
| Treynor Ratio | 0.3194 | |||
| Maximum Drawdown | 70.56 | |||
| Value At Risk | (8.42) | |||
| Potential Upside | 16.49 | |||
| Downside Variance | 33.67 | |||
| Semi Variance | 28.2 | |||
| Expected Short fall | (6.71) | |||
| Skewness | 3.27 | |||
| Kurtosis | 17.23 |
| Risk Adjusted Performance | 0.085 | |||
| Market Risk Adjusted Performance | 0.3294 | |||
| Mean Deviation | 5.64 | |||
| Semi Deviation | 5.31 | |||
| Downside Deviation | 5.8 | |||
| Coefficient Of Variation | 1008.35 | |||
| Standard Deviation | 9.46 | |||
| Variance | 89.58 | |||
| Information Ratio | 0.0854 | |||
| Jensen Alpha | 0.5786 | |||
| Total Risk Alpha | (0.56) | |||
| Sortino Ratio | 0.1393 | |||
| Treynor Ratio | 0.3194 | |||
| Maximum Drawdown | 70.56 | |||
| Value At Risk | (8.42) | |||
| Potential Upside | 16.49 | |||
| Downside Variance | 33.67 | |||
| Semi Variance | 28.2 | |||
| Expected Short fall | (6.71) | |||
| Skewness | 3.27 | |||
| Kurtosis | 17.23 |
Consider Summit Therapeutics' intraday indicators
Summit Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Summit Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 53272.22 | |||
| Daily Balance Of Power | (0.34) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 19.14 | |||
| Day Typical Price | 19.07 | |||
| Price Action Indicator | (0.33) | |||
| Period Momentum Indicator | (0.26) | |||
| Relative Strength Index | 47.89 |
Summit Therapeutics Corporate Filings
8K | 30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 15th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 26th of September 2024 Other Reports | ViewVerify | |
ASR | 19th of September 2024 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
Summit Stock media impact
Far too much social signal, news, headlines, and media speculation about Summit Therapeutics that are available to investors today. That information is available publicly through Summit media outlets and privately through word of mouth or via Summit internal channels. However, regardless of the origin, that massive amount of Summit data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Summit Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Summit Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Summit Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Summit Therapeutics alpha.
Summit Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Summit Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Summit Therapeutics PLC Historical Investor Sentiment
Investor biases related to Summit Therapeutics' public news can be used to forecast risks associated with an investment in Summit. The trend in average sentiment can be used to explain how an investor holding Summit can time the market purely based on public headlines and social activities around Summit Therapeutics PLC. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Summit Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Summit Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Summit Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Summit Therapeutics.
Summit Therapeutics Corporate Management
| Elaine JD | Head Counsel | Profile | |
| Fong Clow | Chief Officer | Profile | |
| Betty Chang | Oncology Research | Profile | |
| Bhaskar Anand | Chief Finance | Profile | |
| Will Black | Head Technology | Profile |
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.